This symposium is intended for a European audience. In the U.S., the IBV Valve System is not approved for emphysema and has a humanitarian device exemption for the treatment of specific post-surgical prolonged air leaks.

Speakers: Robert A. Wise, MD, (Chair), Professor of Medicine, Division of Pulmonary and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, Md; Daniel Sterman, MD, Associate Professor of Medicine, Associate Professor of Medicine in Surgery, Director of Interventional Pulmonology and Clinical Director of the Thoracic Oncology Gene Therapy Program, University of Pennsylvania School of Medicine, Philadelphia; and Arschang Valipour, MD, Assistant Professor, Ludwig Boltzmann Institute for COPD Research, Ethikkommission, Austria.

Presenters: Christopher B. Cooper, MD, Professor of Medicine and Physiology, David Geffen School of Medicine, University of California, Los Angeles; Harvey O. Coxson, PhD, Associate Professor, Department of Radiology, and James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia, Vancouver, British Columbia, Canada; Mark R. Elstad, MD, Chief of Medicine and Director of the Medical Intensive Care Unit, Veterans Affairs Medical Center, and Professor of Medicine, University of Utah School of Medicine, Salt Lake City; Prof. Felix J.F. Herth, MD, PhD, FCCP, Chairman and Head of Pneumology and Respiratory Care Medicine, ThoraxKlinik, University of Heidelberg, Germany; Atul C. Mehta, MB, BS, Vice-Chairman of the Department of Pulmonary and Critical Care Medicine, Head of the Section of Bronchology, and Medical Director of the Lung Transplant Team, Cleveland Clinic; and Daniel A. Nader, DO, FCCP, FACP, Medical Director of the Center for Respiratory Medicine and Assistant Professor of Internal Medicine, Oklahoma State University Center for Health Sciences, and Medical Director of the Lung Cancer Evaluation and Treatment Center, Southwest Regional Medical Center, Oklahoma Cancer Treatment Centers of America, Tulsa

Organizer: Spiration

6:30 to 9:30 p.m.
San Francisco Marriott Marquis: Yerba Buena 8
Controversies in PAH: Exploring Patient Co-Management 
Leading experts in PAH will explore compelling questions in the co-management of PAH patients, from the perspectives of the PH center, rheumatologist and community-based physician. This non-CME symposium will feature a series of real-life patient case studies and multidisciplinary approaches to this difficult disease.

Faculty: Hunter Champion MD, PhD, Associate Professor of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh Medical Center; Jeremy Feldman, MD, Arizona Pulmonary Specialists, Phoenix; Roham Zamanian MD, Assistant Professor of Medicine, Stanford (Calif.) University Medical Center; Lorinda Chung, MD, MS, Assistant Professor of Medicine, Stanford University Medical Center; and Jorge Mercado, MD, St. Vincent’s Health Center, Erie, Pa.

Organizer: Gilead Sciences, Inc.

6:30 to 9:30 p.m.
San Francisco Hilton Union Square: Plaza Room A/B
Pathophysiology of and Approach to Non-PAH PH
Pulmonary hypertension (PH) is not a unitary condition but rather a suite of related diseases with many subtypes, etiologies and comorbidities. Pulmonary arterial hypertension has a notably complex pathophysiology and presents a major challenge of diagnosis and treatment. The most recent clinical classification, that of Dana Point, lists five major subtypes. These subtypes, such as PH secondary to lung diseases (e.g., idiopathic pulmonary fibrosis) and inoperable chronic thromboembolic pulmonary hypertension (CTEPH) may have an even more aggressive clinical course and present even greater challenges. The purpose of this symposium is to describe the epidemiology and pathophysiology of these subtypes of PH and to summarize the clinical data associated with an approach to appropriate management.

Speakers/Presenters: Victor Tapson, MD (Chair), Director of the Duke Center for Pulmonary Vascular Disease and Professor of Medicine in Pulmonary and Critical Care, Duke University School of Medicine, Durham, N.C.; Marc J. Semigran, MD, Medical Director of the Heart Failure and Cardiac Transplant Program, Massachusetts General Hospital Heart Center, Boston, Mass.; Steven Nathan, MD, Medical Director of the Lung Transplant Program and Medical Director of the Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, Va; and Hossein A. Ghofrani, MD, Associate Professor of Internal Medicine, Head of Pulmonary Hypertension and Director of Internal Medicine, University Hospital Giessen, Germany.

Organizer: Bayer HealthCare Pharmaceuticals

6:30 to 9:30 p.m.
San Francisco Hilton Union Square: Continental
MRSA Healthcare-Associated Pneumonia (HCAP): Considerations of Patient Care for MRSA Nosocomial Pneumonia
In the intervening years since the ATS/IDSA guidelines recognized healthcare-associated pneumonia (HCAP) as a novel category of nosocomial pneumonia, clinicians have had the opportunity to evaluate how this new definition of HCAP affects their approach to patient care. In this symposium, leaders in the area of pneumonia and infectious disease will evaluate the current understanding of HCAP due to known or suspected MRSA. In addition, they will explore how an awareness of a patient’s risk factors for MRSA HCAP can influence the choice of initial empiric therapy, especially in light of the higher prevalence of multidrug-resistant pathogens in HCAP. Considerations in the detection and management of this type of pneumonia will be assessed through the presentation of a case study, and an overview of therapeutic options will be discussed.
Speakers: Robert C. Hyzy, MD, Associate Professor in the Department of Internal Medicine and Director of Critical Care Medicine Unit, University of Michigan, Ann Arbor; Michael S. Niederman, MD, Chairman in the Department of Medicine, Winthrop-University Hospital, and Professor of Medicine and Vice-Chairman of the Department of Medicine, State University of New York at Stony Brook; and Julio Ramirez, MD, Chief of the Division of Infectious Diseases, Professor of Medicine, and Director of the Infectious Diseases Fellowship Training Program, University of Louisville (Ky.) School of Medicine
Organizer: Pfizer Inc.

Monday
5:30 to 7 a.m.
San Francisco Marriott Marquis: Yerba Buena 9
Pulmonary Arterial Hypertension: Expert Forum
Pulmonary Arterial Hypertension: This expert Forum will open with an update on the current body of knowledge regarding the pathophysiology and treatment of PAH, followed by case-based presentations regarding PAH therapy. Within the case-based presentations, the expert panel will review how to select a first-line therapy for a patient, patient monitoring and clinical decision-making regarding treatment over time. Please visit booth 211 for more information.

Speaker: Vallerie McLaughlin, MD (Moderator), Professor of Internal Medicine and Director of the Pulmonary Hypertension Program, University of Michigan Health System, Ann Arbor

Organizer: Lung LLC

Tuesday
5:30 to 7 a.m.
San Francisco Marriott Marquis: Golden Gate B
Sedation in the ICU: Confronting Challenges and Applying Best Practices
Recent advances in assessment and management of pain, sedation and delirium in the ICU are explored in this timely symposium. The ABCDE system as well as the pending PAD guidelines will be discussed. The latest clinical findings, outcomes studies and practical methods of implementation will be presented by faculty who have been deeply involved in these clinical approaches.

Speakers: Juliana Barr, MD, FCCM (Chair), Associate Professor of Anesthesia, Stanford (Calif.) University School of Medicine; Timothy D. Girard, MD, MSCI, Assistant Professor of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.; and Yoanna Skrobik, MD, FRCPC, Professor in the Division of Critical Care, Maisonneuve Rosemont Hospital, University of Montreal, Quebec, Canada

Educational Grant Support: Hospira
Organizer: The France Foundation

6:30 to 9:30 p.m.
San Francisco Marriott Marquis: Golden Gate B
COPD Exacerbations: What Can We Do?
Chronic obstructive pulmonary disease (COPD) is associated with an enhanced inflammatory response in the airways and lungs, and exacerbations of the disease contribute to its progression. Newly revised GOLD guidelines for the management of COPD advocate a combined assessment approach based on symptom severity, level of airflow obstruction, and/or history of exacerbations. This symposium will focus on highlighting important revisions to the guidelines as well as reviewing treatment strategies that can benefit COPD patients.

Speakers: Stephen Rennard, MD (Chair), Larson Professor of Medicine, University of Nebraska Medical Center, Omaha; Sanjay Sethi, MD, Professor of Medicine and Chief of the Division Pulmonary, Critical Care and Sleep Medicine, University of Buffalo, and Section Chief for Pulmonary, Critical Care and Sleep Medicine, Veterans Affairs Western New York Healthcare System; and Gary Ferguson, MD, Director of the Pulmonary Research Institute of Southeast Michigan, Livonia

Organizer: Forest Pharmaceuticals, Inc.

6:30 to 9:30 p.m.
San Francisco Marriott Marquis Yerba Buena 7
The Pulmonary Personalized Medicine Challenge
The Pulmonary Personalized Medicine Challenge has been developed by the Johns Hopkins University School of Medicine. This program addresses knowledge/practice gaps regarding personalized medicine, genotyping and pharmacogenomics related to the treatment of asthma, NSCLC and CF. The symposium uses game-based methodologies designed to close knowledge/practice gaps related to personalized treatment of lung diseases.

Speakers: Michael Boyle, MD, FCCP, Associate Professor of Medicine and Director of the Adult Cystic Fibrosis Program, The Johns Hopkins University, Baltimore, Md.; Roy S. Herbst, MD, PhD, Professor of Medicine and of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research, Yale School of Medicine, New Haven, Conn.; and Elliot Israel, MD, Professor of Medicine, Harvard Medical School, and Director of Clinical Research in the Pulmonary Division, Brigham and Women’s Hospital, Boston, Mass.

Educational Grant Support: Vertex Pharmaceuticals, Inc.
Organizer: The Johns Hopkins University in collaboration with DKBmed, LLC